OKI-179

· OnKure, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for OKI-179, covering 2025-03-07 to 2025-03-07. Get the full timeline:

Most recent: Clinical Trial Update: NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) [Phase 1, Phase 2]

See pricing